96.34 <%= Resources.Global.txtDown %>
Updated 16:40:00
Change % -0.43% Stock price decreasing
Change -0.42 Stock price decreasing
Volume 389,628
High 97.78
Low 95.50
Open 96.78
ISIN BE0003818359
Prev close 96.76
# of shares 54.30M
Market cap 5,231.18M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  96.34 -3.4% Stock price decreasing 7.0% Stock price increasing 12.7% Stock price increasing 17.3% Stock price increasing 15.7% Stock price increasing
Powered by TradingView

News about Galapagos

  • English
  • Regulatory news

Company profile

Galapagos is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
24 September 2018 21:11:17
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB3 - 2018-09-24 22:11:17 - 2018-09-24 21:11:17 - 1000 - Website: OKAY